• Proliferative activity and receptor status of benign and borderline epithelial ovarian tumors

Proliferative activity and receptor status of benign and borderline epithelial ovarian tumors

HEALTH OF WOMAN. 2016.6(112):158–164; doi 10.15574/HW.2016.112.158 
 

Proliferative activity and receptor status of benign and borderline epithelial ovarian tumors 
 

Sukhanova A. A., Nespryadko S. V., Melnik M. M., Yegorov M. Yu.

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev

The National Cancer Institute Ministry of health of Ukraine, Kyiv

National children's specialized hospital "OKHMATDYT", Kyiv 
 

The aim was to study the expression features of proliferation marker Ki-67 and estrogen receptor (ER) in cells of benign (BeEOT) and borderline epithelial ovarian tumors (BoEOT) and to determine their value for clinical prognosis and tumor justification tactics for further treatment.


Patients and methods. Studies conducted on the material of 60 patients with BeEOT and BoEOT who underwent examination and treatment during 2010-2016. It was studied specific menstrual dysfunction, ultrasound data and colour doppler research, the performance of serum tumor markers, morphological and immunohistochemical studies were conducted to determine the Ki-67 and ER in samples of BeEOT and BoEOT.


Results. The results of Ki-67 expression determining indicate the heterogeneity of individual performance fluctuations from 0% to 15%. The average value of the proliferation index (PI) was 5.07±0.47%, the median (ME) was 4%. It is determined that almost all BeEOT (96.7%) was marked by lower PI<10%, while 5 of 10 serous borderline cystadenomas (50%) and 1 of 10 mucinous borderline cystadenomas (10%) were attributed to high proliferation (IPі10%) tumors. It is found that in most cells of BeEOT and BoEOT was available the expression of ER. Individual values of ER expression level ranged from 2.0% to 90,0%. The average value of the IM (index marks) ER was 45.08±3.2%, ME=49.5%. It is found a significant decrease (p<0.05) in the ER expression level in EOT of late reproductive age patients compared with younger ones, as well as in cells of BoEOT compared to BeEOT.


Conclusion. Some associative connection between the expression of Ki-67 and ER with EOT malignancy potential demonstrates the need to use them for tumor course prognosis and appointment of adequate individualized treatment strategy of patients.


Key words: benign and borderline ovarian tumors, immunohistochemical studies, Ki-67, estrogen receptors.


REFERENCES

1. Abdullaeva LM. 2012. Kliniko-gistologicheskaya harakteristika dobrokachestvennyih obrazovaniy yaichnikov. Zdorove zhenschinyi 2(68):197–198.

2. Amandosova AN. 2013. Spetsifichnost onkomarkera SA125 pri zabolevaniyah yaichnika. AktualnI pitannya farmatsevtichnoYi I medichnoYi nauki ta praktiki 2:46.

3. Babichenko II, Kovyazin VA. 2008. Novyie metodyi immunogistohimicheskoy diagnostiki opuholevogo rosta: Ucheb. posobie. M, RUDN:109.

4. Bozhenko OIu. 2012. Porivnialnyi analiz zastosuvannia onkomarkeriv SA125 ta NE4 pry dyferentsialnii diahnostytsi pukhlyn yaiechnykiv. Zdorove zhenshchynы 8(74):183–186.

5. Volkova AV, Chepik OF, Bahidze EV, Ten VP. 2005. Rol antigena KI-67, mutirovannogo gena-supressora r53 i mitoticheskoy aktivnosti opuholi v opredelenii prognoza granulezokletochnyih opuholey yaichnikov vzroslogo tipa. Voprosyi onkologii 51;4:455–459.

6. Yehorov OO. 2012. Laparoskopichne orhanozberihaiuche likuvannia pohranychnykh pukhlyn i rannoi onkolohichnoi patolohii yaiechnykiv. Tavrycheskyi medyko-byolohycheskyi vestnyk 2;1(58):115–117.

7. Nasedkin AG. 2007. Klinicheskaya kartina i morfologiya yaichnikovogo pridatka pri razlichnyih vidah kist yaichnikov. Sibirskiy meditsinskiy zhurnal 2:101–104.

8. Nosenko EN. 2008. Nekotoryie voprosyi sovremennoy klassifikatsii, epidemiologii i patogeneza dobrokachestvennyih kistoznyih obrazovaniy yaichnikov u devochek-podrostkov i zhenschin aktivnogo reproduktivnogo vozrasta. Gazeta «Novosti meditsinyi i farmatsii». Ginekologiya (253) (tematicheskiy nomer). http://www.mif-ua.com/archive/article/5992

9. Nosenko OM. 2013. Morfolohichni aspekty dotsilnosti provedennia orhanozberihaiuchykh operatsii u zhinok reproduktyvnoho viku z kistoznymy dobroiakisnymy utvorenniamy yaiechnykiv, zatsikavlenykh u realizatsii reproduktyvnoi funktsii. Medyko-sotsialni problemy sim’i 2(18):51–55.

10. Pozharisskiy KM, Leenman EE. 2004. Prognosticheskoe i predskazatelnoe znachenie immunogistohimicheskih markerov pri onkologicheskih zabolevaniyah: Materialyi III s'ezda onkologov i radiologov SNG, Minsk, 25–28 maya 2004 g. V 2 ch. Ch. 1. Mn, ODO «Tonpik»:113–116.

11. Repina NB. 2005. Kliniko-morfologicheskaya i immunogistohimicheskaya harakteristika seroznyih opuholey yaichnika: Avtoref. dis. … kand. med. nauk: 14.00.14. Onkologiya. Ryazan.

12. Rozhkovskaya NN, Gladchuk IZ, Aleksandrov AL. 2007. Vozmozhnosti kompleksnogo ultrazvukovogo obsledovaniya v dooperatsionnoy diagnostike opuholevidnyih obrazovaniy yaichnikov. Reproduktivnoe zdorove zhenschinyi 2:22–24.

13. Shatseva TA, Muhina MS. 2004. Antigen KI-67 v otsenke opuholevoy proliferatsii. Ego struktura i funktsii. Voprosyi onkologii 50;2:157–164.

14. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, QuallsCR, Chavez A, Prossnitz ER, Verschraegen CF. 2009, Sep. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol. 114(3):480–5. http://dx.doi.org/10.1016/j.ygyno.2009.05.045; PMid:19560192 PMCid:PMC2756056

15. Brown DL. 2007. A practical approach to the ultrasound characterization of adnexal masses. Ultrasound Q 23:87–105. http://dx.doi.org/10.1097/01.ruq.0000263849.45926.cb; PMid:17538485

16. Buchynska LG, Iurchenko NP, Grinkevych VM, Nesina IP, Chekhun SV, Svintsitsky VS. 2009, Mar. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Exp Oncol. 31(1):48–51. PMid:19300417

17. Cйcile Le Page, David G Huntsman, Diane M. Provencher and Anne-Marie Mes-Masson. 2010. Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommen-dation for Future Studies. Cancers. 2:913–954. http://dx.doi.org/10.3390/cancers2020913; PMid:24281100 PMCid:PMC3835111

18. Chu S, Mamers P, Burger HG, Fuller PJ. 2000, Mar. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab. 85(3):1200–5. http://dx.doi.org/10.1210/jcem.85.3.6449http://dx.doi.org/10.1210/jc.85.3.1200; PMid:10720062

19. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. 2007. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Ginecol 19(1):3–9. http://dx.doi.org/10.1097/GCO.0b013e328011a21f; PMid:17218844

20. Douglas L. Brown, Kika M. Dudiak MD, and Faye C. Laing, MD. Adnexal Masses. 2010, Feb. US Characterization and Reporting. Radiology 254(2):342–54. http://dx.doi.org/10.1148/radiol.09090552; PMid:20089722

21. du Bois A, Ewald-Riegler N, du Bois O et al. 2009. Borderline tumors of the ovary: A systematic review. Geburtsh Frauenheilk. 69:807–833. http://dx.doi.org/10.1055/s-0029-1186007

22. Gursan N, Sipal S, Calik M, Gundogdu C. 2009, Apr. P53, bcl-2, Ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. Eurasian J Med. 41(1):10–4. PMid:25610057 PMCid:PMC4261648

23. Kupesic S, Plavsic BM. 2006, Sep-Oct. Early ovarian cancer: 3-D power Doppler. Abdom Imaging. 31(5):613–9. http://dx.doi.org/10.1007/s00261-005-0398-1; PMid:16447081

24. Longacre TA, Gilks CB. 2009. Surface epithelial stromal tumours of ovary. In: Nucci MR, Olivia E (eds), Gynecologic pathology, Elsevier Churchill Livingstone:390–450.

25. Luminiюa Nicoleta Giurgea, Carmen Ungureanu, Maria Sultana Mihailovici. 2012. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Corre-lation with clinicopathological factors. Rom J Morphol Embryol. 53(4):967–973. PMid:23303020

26. Naik PS, Deshmukh S, Khandeparkar SG, Joshi A, Baba-nagare S, Potdar J, Risbud NS. 2015, Oct-Dec. Epithelial ovarian tumors: Clinicopatho-logical correlation and immunohistochemical study. J Midlife Health 6(4):178–83. http://dx.doi.org/10.4103/0976-7800.172349; PMid:26903759 PMCid:PMC4743281

27. Ouellet V et al. 2008. Immuno-histochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer. 8:346. http://dx.doi.org/10.1186/1471-2407-8-346; PMid:19032793 PMCid:PMC2610034

28. Piek JM, van Diest PJ, Verheijen RH. 2008. Ovarian carcinogenesis: An alternatine hypothesis. Adv Exp Med Biol 622:79–87. http://dx.doi.org/10.1007/978-0-387-68969-2_7; PMid:18546620

29. Shih Iem, Kurman RJ. 2004, May. Ovarian tumorogenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 164(5):1511–8.

30. Sylvia Mary T, Kumar S, Dasari P. 2012, Jan-Mar. The expression immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol. 55(1):33–7. http://dx.doi.org/10.4103/0377-4929.94852; PMid:22499297